ReBio Pharma today announced that it will be delivering a poster presentation at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held May 5-9 in Seattle, Washington, USA.

ReBio Pharma has announced that it will present an abstract entitled “Optimizing Injectable in situ Forming Implants for Sustained Release of Ophthalmic Therapeutics” at the 2024 Annual Controlled Release Society (CRS) Meeting, to be held July 8-12 in Bologna, Italy.

ReBio Pharma has announced the appointment of Kristof Kunzmann, MBA, as Chief Financial Officer (CFO). Kunzmann is a seasoned healthcare executive who comes to ReBio Pharma with more than 12 years of experience as CFO and COO of multi-site clinics and specialized lab businesses.

ReBio Pharma announced today that Patrick Aisher has joined the team as a Non-Executive Member of its Board of Directors. Aisher is Chairman of Kinled Holding in Hong King, which retains a portfolio of more than 100 investments in the life science, digital, and financial technology industries, and…

ReBio today announced that is has completed a Type B pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) regarding ReBio’s proposed development program for RBLP in the treatment of mild to moderate primary open-angle glaucoma.

ReBio today announced today the formation and members of its Scientific Advisory Board (SAB), comprised of leaders in ophthalmology and ophthalmic drug delivery

ReBio today announced that it has received a 410K Euros funding from Business Finland to support the development of SiSu®, ReBio’s proprietary phase-inverting anhydrous liquid polymer formulation platform, for the treatment of chronic eye diseases.

ReBio Technologies Ltd. announced today that it closed a $2 million seed round, and welcomed WI Harper (WIH) as new investors.